The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer
 
Axel Bex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Speakers' Bureau - Ipsen
Research Funding - Pfizer (Inst)
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Robert Uzzo
Consulting or Advisory Role - Merck; Merck; Pfizer
 
Xiaobin Tang
Employment - Genentech
Stock and Other Ownership Interests - Amgen; Atreca; Lyell Immunopharma; Roche
Travel, Accommodations, Expenses - Genentech
 
Zoe June Assaf
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche; Immunocore
Research Funding - Genentech/Roche
Travel, Accommodations, Expenses - Genentech
 
Sarita Dubey
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
 
Erik T. Goluboff
Employment - Genentech
 
Corey Carter
Employment - Genentech
 
Romain Banchereau
Stock and Other Ownership Interests - Roche
 
Mahrukh A Huseni
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Patents, Royalties, Other Intellectual Property - I hold patents as an employee of Roche/Genentech.
Travel, Accommodations, Expenses - Roche/Genentech
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Brian I. Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai